INVEGA® is indicated for the Treatment of schizophrenia and the Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants.
Efficacy was established in adults in three 6-week trials and one maintenance trial in patients with schizophrenia and in two 6-week trials in patients with schizoaffective disorder.